Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seriously is it more a new trend this year selling wave programs on any bio news runs, and then some sporting selling in general for mass correction??
NICE POWER HOUR MNGA !
RITT-low float news today
LIQD 1.67 mate.
LIQD 1.87 big news out
I hope everyone was able to read this article before today
http://investorslive.com/2014/05/19/the-worst-press-release-you-could-get-if-you-believe-in-fortitude-group-inc-frtd/
NURO- PR..DPN launch Japan
NURO-looks like a dead bottom imo..LOW float
Well then add JVA.
BCCI CRVP-Coffee Prices on Rise
http://rt.com/usa/160016-coffee-rust-fungus-raises-prices/
>>>>GERN 1.95 bio tech bottom bouncer
Pingify International Inc. (PGFY) Halts and How You Could Have Predicted It Too http://investorslive.com/2014/05/14/pingify-international-inc-pgfy-halts-and-how-you-could-have-predicted-it-too/
Get the tweetdeck once you do...free
(& an eye opener into what often moves microcaps temporarily)
He actually gives away alot of free info via Twitter
Never twittered but will get on it, thanks!
I tweet too twitter.com/investorslive
Ok Ok do not get too big for this board, I mean just a few crumbs will do.
congrats on the USA Today mention...that's all it takes to get the number of followers to increase rapido...
Huge play NVIV congrats all
went long on NVIV looking to accum dips into close for a gapper
PMRS 0.0069 imo, new website up with 5 hour high, weed in a bottle. Ticker change tomorrow, sweet chart to boot.
PEIX popping & AMTX should also get some legs on GPRE nice earnings beat after hours.
AMRN 1.65 heads up
FOLD-positive phase 3 PR
Wooah momma indeed. lol How is your contribution to humanity doing? She must be a cutie. Twitter wow . ModernRock tweets humm Who would have thunk it.
GNBT time coming....
see the first two AE37 items......
Abstract Announcements
Abstract Announcements and Exceptions
Confidentiality Policy Exceptions
According to ASCO's Confidentiality Policy, each abstract submitted to the Annual Meeting is confidential from the time of submission until the date and time when ASCO makes the abstract publicly available. Under rare, extenuating circumstances requiring a formal application, abstracts may receive an Exception to ASCO’s Confidentiality Policy. These formal Exceptions require approval by ASCO prior to the information being made public.
The following abstracts have received formal Exceptions to ASCO’s Confidentiality Policy for the 2014 ASCO Annual Meeting:
Abstract #613
"Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy."
Abstract #638
"Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients."
Abstract #6005
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).
Abstract #8000
"Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial."
Abstract #LBA8006^
"REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy."
Abstract #9008a
"Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma."
Abstract #9011^
“COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma.”
Wooooah momma how are you doing! We all moved on to Twitter now. My twitter name same "modern_rock" and i don't check ihub anymore. I can post freely on twitter without being censored!
IBIO + 25% :)
you can run but you can't hide...
CHEWY just unreal! 10 years later you still stalking me.
IBIO china patent newssss
Hey Rock..long time You still trading otc's? Now where is EVO? lol
CWTRQ DOUBLE :) CONGRATS ALL
I am sorry I missed the trade. NATEEEEEEEEEEEE lol
CWTRQ now on HODs .084 from low .06s
Followers
|
173
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2812
|
Created
|
12/09/12
|
Type
|
Premium
|
Moderator nateeeeee | |||
Assistants harbs Modern_Rock SyNaPzE |
Nathan Michaud, a.k.a. InvestorsLive and founder of InvestorsUnderground, has been trading the markets since 2003. His first Web site, InvestorsLive.com, was originally created as a place to evaluate potential trades and offer general market trading ideas, as well as a daily scan of stocks on watch for the following day.
Posts Today
|
0
|
Posts (Total)
|
2812
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |